Please use this identifier to cite or link to this item: https://doi.org/10.1186/s12913-021-06056-5
Title: A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation
Authors: Fellenor, John
Britten, Nicky
Courtenay, Molly
Payne, Rupert A
Valderas, Jose 
Denholm, Rachel
Duncan, Polly
McCahon, Deborah
Tatnell, Lynn
Fitzgerald, Richard
Warmoth, Krystal
Gillespie, David
Turner, Katrina
Watson, Margaret
Keywords: Science & Technology
Life Sciences & Biomedicine
Health Care Sciences & Services
Medicines optimisation
Polypharmacy
Deprescribing
Patient concerns
Non-medical prescribing
Nominal group technique
Issue Date: 13-Jan-2021
Publisher: BMC
Citation: Fellenor, John, Britten, Nicky, Courtenay, Molly, Payne, Rupert A, Valderas, Jose, Denholm, Rachel, Duncan, Polly, McCahon, Deborah, Tatnell, Lynn, Fitzgerald, Richard, Warmoth, Krystal, Gillespie, David, Turner, Katrina, Watson, Margaret (2021-01-13). A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation. BMC HEALTH SERVICES RESEARCH 21 (1). ScholarBank@NUS Repository. https://doi.org/10.1186/s12913-021-06056-5
Abstract: Background: Up to 50% of medicines are not used as intended, resulting in poor health and economic outcomes. Medicines optimisation is ‘a person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines’. The purpose of this exercise was to co-produce a prioritised research agenda for medicines optimisation using a multi-stakeholder (patient, researcher, public and health professionals) approach. Methods: A three-stage, multiple method process was used including: generation of preliminary research questions (Stage 1) using a modified Nominal Group Technique; electronic consultation and ranking with a wider multi-stakeholder group (Stage 2); a face-to-face, one-day consensus meeting involving representatives from all stakeholder groups (Stage 3). Results: In total, 92 research questions were identified during Stages 1 and 2 and ranked in order of priority during stage 3. Questions were categorised into four areas: ‘Patient Concerns’ [e.g. is there a shared decision (with patients) about using each medicine?], ‘Polypharmacy’ [e.g. how to design health services to cope with the challenge of multiple medicines use?], ‘Non-Medical Prescribing’ [e.g. how can the contribution of non-medical prescribers be optimised in primary care?], and ‘Deprescribing’ [e.g. what support is needed by prescribers to deprescribe?]. A significant number of the 92 questions were generated by Patient and Public Involvement representatives, which demonstrates the importance of including this stakeholder group when identifying research priorities. Conclusions: A wide range of research questions was generated reflecting concerns which affect patients, practitioners, the health service, as well the ethical and philosophical aspects of the prescribing and deprescribing of medicines. These questions should be used to set future research agendas and funding commissions.
Source Title: BMC HEALTH SERVICES RESEARCH
URI: https://scholarbank.nus.edu.sg/handle/10635/236316
ISSN: 1472-6963
DOI: 10.1186/s12913-021-06056-5
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation.pdfPublished version973.9 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.